Cellectar Biosciences (CLRB) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Niki BioSolutions (NIKI) over the past year, losing 70.7% versus a loss of 82.1%. Over five years, NIKI leads with a -98.3% price change compared with -99.5% for CLRB. Cellectar Biosciences is the larger company by market cap ($13.7 million vs $12.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | NIKI |
|---|---|---|
| Share price | $1.45 | $4.00 |
| Market cap | $13.71M | $12.47M |
| 1-day change | +3.57% | -7.41% |
| YTD return | -52.54% | -59.25% |
| 1-year return | -70.71% | -82.07% |
| 5-year return | -99.49% | -98.33% |
| EPS (TTM) | $-3.46 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $24.00 |
| 52-week low | $1.34 | $4.00 |
| Distance from 52-week high | -71.40% | -83.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +693.10% | — |
| Average volume | 63.86K | 157.52K |
| Shares outstanding | 9.45M | 2.94M |
| Employees | 11 | 1 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLRB has outperformed NIKI by 11.4 percentage points over the past year.
- The two companies sit in different sectors: Cellectar Biosciences in Health Care and Niki BioSolutions in Industrials.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
CLRB vs NIKI FAQ
Which is bigger, Cellectar Biosciences or Niki BioSolutions?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.71M compared with $12.47M for Niki BioSolutions (NIKI).
Which stock has performed better over the past year, CLRB or NIKI?
CLRB returned -70.71% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Niki BioSolutions in the same industry?
No. Cellectar Biosciences is in the Health Care sector, while Niki BioSolutions is in Industrials.